8 citations
,
June 2017 in “Steroids” This study evaluated novel steroid compounds for their ability to inhibit 5α-reductase, showing that compound 16a significantly reduced rat prostate weight more than epristeride and exhibited excellent in vitro inhibitory potency, indicating its potential as a lead candidate for further benign prostatic hyperplasia drug research.
April 2017 in “Journal of Pharmaceutical Investigation” In this study, the administration of indole-based compounds, particularly L-Tryptophan and Tryptophol, to a PCOS-induced rat model resulted in an increased number of healthy ovarian follicles and a reduction in ovarian cysts compared to untreated rats, suggesting potential therapeutic efficacy.
3 citations
,
December 2018 in “Biomedical and pharmacology journal/Biomedical & pharmacology journal” This study found that compound 3 derived from aza-bicyclo-carboxylic acid may exert a cardioprotective effect by reducing infarction area in myocardial ischemia-reperfusion injury, potentially involving A1-adenosine receptor activation and changes in cAMP levels.
11 citations
,
August 1997 in “Expert Opinion on Therapeutic Patents” This review discusses nearly 70 patent applications for the treatment of androgenetic alopecia and other hair conditions, highlighting the mechanisms of action explored but reports no clinical results.
November 2025 in “Advanced Healthcare Materials” This study found that incorporating CTA2-BADG, a modified hair-rebonding compound, into damaged hair significantly improved surface morphology and tensile strength by using charge-conversion chemistry to enhance penetration into the hair shaft.